Successful treatment of a VIPoma by continuous subcutaneous infusion of somatostatin analogue (SMS 201-995).
A case with WDHA syndrome due to VIPoma is reported. Injection of somatostatin analogue SMS 201-995 was followed by prompt suppression of vasoactive intestinal polypeptide levels (VIP), decreased stool volume, and restoration of the serum potassium concentration to normal. Long-term treatment with SMS 201-995 for up to 20 weeks produced excellent clinical control and a decrease in tumour size. No adverse effects were noted except for localized pain at the site of injection. This was overcome by using a continuous subcutaneous infusion pump which also enabled the effective daily dosage to be reduced and thereby adverse reactions to be avoided.
Niitsu
Y
Y
Department of Internal Medicine, Sapporo Medical College, Japan.
Goto
Y
Y
Maeda
M
M
Tsushima
N
N
Watanabe
N
N
Kohgo
Y
Y
Urushizaki
I
I
D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D003969:Vipoma / Q000188:drug therapy*
D015282:Octreotide